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Summary
 
Dipeptidyl peptidase IV (DPPIV) is a cell surface peptidase expressed by normal melanocytes,
 
epithelial cells, and other cells. Malignant cells, including melanomas and carcinomas, frequently
lose or alter DPPIV cell surface expression. Loss of DPPIV expression occurs during melanoma
progression at a stage where transformed melanocytes become independent of exogenous
growth factors for survival. Tetracycline-inducible expression vectors were constructed to ex-
press DPPIV in human melanoma cells. Reexpressing DPPIV in melanoma cells at or below
levels expressed by normal melanocytes induced a profound change in phenotype that was char-
acteristic of normal melanocytes. DPPIV expression led to a loss of tumorigenicity, anchorage-
independent growth, a reversal in a block in differentiation, and an acquired dependence on
exogenous growth factors for cell survival. Suppression of tumorigenicity and reversal of a block
in differentiation were dependent on serine protease activity, assessed using mutant DPPIV
molecules containing serine
 
®
 
alanine substitutions. Surprisingly, dependence on exogenous
growth factors was not dependent on serine protease activity. Reexpression of either wild-type
or mutant DPPIV rescued expression of a second putative cell surface serine peptidase, fibroblast
 
activation protein 
 
a
 
, which can form a heterodimer with DPPIV. This observation suggests that
rescue of fibroblast activation protein 
 
a
 
 may play a role in regulating growth of melanocytic
cells. These results support the view that downregulation of DPPIV is an important early event
in the pathogenesis of melanoma.
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D
 
ipeptidyl peptidase IV (DPPIV)
 
1
 
 is a cell surface pepti-
dase that is expressed on epithelia, melanocytes, and T
cells (1–3). It is a type II membrane glycoprotein that has
multiple properties, including serine protease activity and
the ability to bind adenosine deaminase and extracellular ma-
trix components (2–4). Because it binds to adenosine deami-
nase, DPPIV has also been called adenosine deaminase binding
 
protein or adenosine deaminase complexing protein (4, 5).
DPPIV expression on T cells has been designated CD26 (3).
It has been recognized for several decades that expression
of DPPIV can be extinguished or altered on cancer cells
(6–8). Loss or alteration of membrane expression of DPPIV
has been reported in prostate, colorectal, lung, and hepato-
cellular carcinomas and melanomas (2, 6–13). DPPIV ex-
pression during malignant transformation has been best char-
acterized in melanocytic cells. DPPIV is expressed in vitro
and in vivo by normal melanocytes but not by melanoma,
the malignant counterpart (2, 13). Previous studies have
shown that expression of DPPIV is lost as melanocytes are
transformed into melanoma cells (2, 13, 14). Loss of DPPIV
expression probably occurs at an early stage of melanoma
progression as melanocytes transform into melanoma cells
(2). Specifically, DPPIV is expressed by cutaneous melano-
 
cytes and common nevi but is not detected in vivo or in vitro
on cells from primary or metastatic melanomas. In an in vitro
system that sequentially transformed melanocytes in defined
steps, loss of DPPIV expression occurred concomitantly with
the emergence of growth factor independence (13, 14).
Despite these correlative observations both in vivo and
in vitro, a role for DPPIV in regulating the malignant pheno-
type has not been shown. We report that reexpression of
DPPIV in human melanoma cells at levels comparable to
 
those found in normal melanocytes produced profound
phenotypic changes. These included abrogation of tumor-
igenicity, reemergence of requirements for exogenous growth
 
1
 
Abbreviations used in this paper:
 
 dox, doxycycline; DPPIV, dipeptidyl pep-
tidase IV; FAP
 
a
 
, fibroblast activating protein 
 
a
 
; TRP, tyrosinase-related
protein; TUNEL, TdT-mediated dUTP-biotin nick-end labeling. 
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factors to maintain cell survival, and removal of a block in
cell differentiation. Using a point mutation in the active
serine protease domain of DPPIV, we observed that serine
peptidase activity was required for most effects but not for
cell survival. Reexpression of DPPIV rescued expression of
a second putative surface peptidase, fibroblast activation
protein 
 
a
 
 (FAP
 
a
 
) (15), suggesting that expression of this
second molecule contributes to effects on cell survival in
malignant cells.
 
Materials and Methods
 
Wild-Type and Mutant Plasmid Constructs.
 
Tetracycline-inducible
expression vectors pUHG16-3 and pUHD172-1neo were pro-
vided by Hermann Bujard (Zentrum für Molekulare Biologie der
Universität Heidelberg, Heidelberg, Germany) (16). The plasmid
pUHG16-3 has a cytomegalovirus minimal promoter fused to a
tetracycline operator (teto). Transcription is activated by the re-
verse tet repressor in the presence of tetracycline or doxycycline
(dox). pUHD172-1neo has a neomycin resistance gene and re-
verse tetracycline-controlled transactivator (16). Full length
cDNA (2.3 kb) of human DPPIV was amplified by PCR and
subcloned into the XbaI site of pUHG16-3 to create pDPPIV.
The DNA sequence was identical to the human DPPIV se-
quences, available from EMBL/GenBank/DDBJ under accession
number M74777. The orientation of the insert was confirmed by
DNA sequencing and restriction enzyme digests. Mutant DPPIV
(pmuDPPIV, producing amino acid substitution of alanine for
serine at codon 630, was constructed using the QuickChange™
Site-Directed Mutagenesis Kit (Stratagene, Inc.). The oligonucle-
otide primers used for site-directed mutagenesis were 5
 
9
 
-GCA
ATT TGG GGC TGG GCA TAT GGA GGG TAC-3
 
9
 
 and 5
 
9
 
-
GTA CCC TCC ATA TGC CCA GCC CCA AAT TGC-3
 
9
 
.
Mutants were identified by DNA sequencing.
 
Establishment of Human Melanoma Cells Expressing DPPIV.
 
Human melanoma cells and melanocytes were established and cul-
tured as described (17–19). Human melanoma cell lines MEL-22a,
SK-MEL-28, and SK-MEL-29 were cotransfected with plasmid
pUHD 172-1neo and empty vector pUHG16-3, pDPPIV, or
pmuDPPIV. Lipofectamine reagent was used for transfections as
described by the manufacturer (GIBCO BRL Life Technolo-
gies).
 
Immunofluorescence Microscopy and Flow Cytometry.
 
Cells were
grown on chamber slides (Nunc, Inc.) and then stained with mAb
S27 (4 
 
m
 
g/ml) against DPPIV or mAb TA99 against gp75
 
TRP-1 
 
and
incubated with FITC-conjugated rabbit anti–mouse IgG (DAKO
Corp.). Stained cells were viewed with a Nikon Optiphot micro-
scope. Flow cytometry was performed using FACScan™ (Becton
Dickinson). Cells were stained with S27 mAb or F19 mAb (anti-
FAP
 
a
 
) (20) and FITC-conjugated rabbit anti–mouse IgG.
 
Immunoprecipitation and Western Blot Analysis.
 
For immuno-
precipitation assays (21), cells were cultured in medium contain-
ing [
 
35
 
S]methionine (NEN Dupont) for 18 h, and cell lysates were
precipitated with anti-DPPIV mAb S27. Western blot analysis
was performed as described (21) using rabbit PEP7H antibody
against human tyrosinase (a gift of Vincent Hearing, National In-
stitutes of Health [NIH], Bethesda, MD).
 
Dipeptidyl Peptidase Enzyme Activity, In Situ Apoptotic Cell Detection
by TdT-mediated dUTP-Biotin Nick-End Labeling Assay, Cell Cycle
Analysis, Anchorage-independent Studies, and Growth Curves.
 
DPPIV
peptidase activity was measured by colorimetric assay (22). In
brief, cells expressing DPPIV in the presence (2 
 
m
 
g/ml for 2–4 d)
 
or absence of dox were suspended in lysis buffer containing 0.5%
CHAPS (3-[3-cholamidopropyl]dimethyl-ammonio-1-propane-
sulfonate). Untransfected and vector-transfected cells were used as
controls. 30 
 
m
 
l of cell lysates was incubated with 10 
 
m
 
l of 10 mM
substrate, Gly-Pro 
 
p
 
-nitroanilide (Sigma Chemical Co.), at 37
 
8
 
C
for 30 min. Reactions were stopped with 250 
 
m
 
l of 10% TCA,
and the supernatants were mixed with 250 
 
m
 
l of 0.1% NaNO
 
2
 
and incubated at room temperature for 3 min followed by addi-
tion of 250 
 
m
 
l 0.5% ammonium sulfamate. At the end of a 2-min
incubation, 500 
 
m
 
l of 0.05% 
 
N
 
-(1-naphthyl)ethylenediamine was
added, and 
 
p
 
-nitroaniline release was measured at 540 nm. Pepti-
dase activities were standardized based on protein concentration
and also on cell number. Protein concentrations were measured
by the Bradford assay using the BioRad DC protein assay kit.
Specific activities were expressed as picomoles per microgram
protein per minute.
For apoptosis assays, cells were grown in plain RPMI medium
without serum for 3, 8, or 15 d. TdT-mediated dUTP-biotin
nick-end labeling (TUNEL) assay was performed using the AP-
OPTAG kit (Oncor, Inc.). Percent apoptosis was calculated by
FACScan™ (Becton Dickinson). Evidence of apoptosis and per-
cent of cells in each phase of the cell cycle was analyzed by Cell-
FIT and PC-LYSIS™ software (Becton Dickinson).
Growth curves were determined as described (18). In brief,
cells were plated at a density of 10
 
4
 
 cells per well in triplicate in
24-well plates. Every 3 d, cultures were refed with fresh media.
Cells were trypsinized daily for 10–12 d and stained with trypan
blue, and viable cells were counted. Time of doubling was deter-
mined from a least squares regression fit of cell number versus
time during the logarithmic growth phase.
Colony formation was performed in soft agar. In brief, the top
layer, consisting of 5,000 viable cells suspended in 0.3% agarose
and RPMI 1640 with 20% FCS, was overlaid on a 1% agarose
layer in 35-mm culture plates. 14 d after seeding, colonies 
 
$
 
200
 
m
 
m in diameter were counted under a light microscope. The data
are presented as the mean of triplicate plates.
 
Tumor Growth In Vivo.
 
Nude mice (
 
nu/nu
 
, BALB/c) were
injected subcutaneously with 3 
 
3
 
 10
 
6
 
 cells (either MEL-22a or
SK-MEL-29) expressing mutant or wild-type DPPIV and control
cells. Five to six animals were used for each group. The tumors
were measured every 2–3 d along the greatest diameter. All
mouse experiments were performed under protocols approved by
the Institutional Animal Care and Utilization Committee of Me-
morial Sloan-Kettering Cancer Center according to NIH animal
care guidelines.
 
Results
 
Establishment and Characterization of Melanoma Cells Ex-
pressing DPPIV.
 
To define a possible functional role of
DPPIV in melanocytic cells, we established melanoma cells
that expressed DPPIV in an inducible manner using tetra-
cycline-inducible vectors. Three human melanoma cell
lines, MEL-22a, SK-MEL-28, and SK-MEL-29, derived
from metastatic lesions of different patients, were selected
for study. These melanoma cell lines are representative of
more than 150 melanoma cell lines that we have tested that
do not express detectable DPPIV glycoprotein (reference 2
and our unpublished data). In addition, the growth and dif-
ferentiation of these three melanoma lines have been well
characterized (17, 18). These cell lines represent different 
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stages of melanocyte/melanoma differentiation (17). They
are either completely nonpigmented with a phenotype that
corresponds to an immature stage of melanocyte differenti-
ation (MEL-22a) or minimally pigmented with a pheno-
type of an intermediate stage of melanocyte differentiation
(SK-MEL-28 and SK-MEL-29; reference 17 and 18; Table I).
Because we had trouble isolating stable transfectants ex-
pressing DPPIV using constitutive vectors, we used an in-
ducible vector system. Melanoma cells were cotransfected
with a neomycin-resistant regulator plasmid and tetracy-
cline-inducible vector carrying: (a) the full length wild-
type (wt)DPPIV cDNA, (b) a mutant (mut)DPPIV having
minimal serine protease activity (substitution of alanine for
serine at codon 630 altering the catalytic domain), or (c) a
control empty vector (16). Multiple clones that expressed
each cDNA construct were isolated for each cell line (Tables I
and II). Transfected clones expressing empty vector and
mutDPPIV were always relatively easy to derive, and at
least three clones were established for each melanoma cell
line. Transfected clones expressing wtDPPIV were more dif-
 
Table I.
 
Characteristics of Human Melanoma Cells Expressing Wild-Type and Mutant DPPIV
 
Cell line No. clones tested Morphology Pigmentation
MEL-22a
Parental
 
2
 
Short spindle/epithelioid
 
2
 
Vector 6 Short spindle/epithelioid
 
2
 
wtDPPIVhi 3 Long spindle/bipolar
 
111
 
wtDPPIVmed 2 Long spindle/bipolar
 
11
 
wtDPPIVlow 2 Short spindle
 
2
 
mut DPPIV 3 Short spindle/epithelioid
 
2
 
SK-MEL-28
Parental
 
2
 
Long spindle/bipolar
 
2
 
Vector 4 Long spindle/bipolar
 
2
 
wtDPPIV 3 Polydendritic
 
111
 
mutDPPIV 3 Long spindle/bipolar
 
2
 
SK-MEL-29
Parental
 
2
 
Long spindle/bipolar
 
2
 
Vector 4 Long spindle/bipolar
 
2
 
wtDPPIV 2 Polydendritic
 
11
 
mutDPPIV 3 Long spindle/bipolar
 
2
 
Morphology nomenclature is described in the text (references 17, 18). Pigmentation: 
 
2
 
, no detectable pigmentation observed in cell pellet (SK-
MEL-28 and SK-MEL-29 had pigment detectable only by melanin assays; 18). 
 
1
 
, 
 
11
 
, and 
 
111
 
, lighter, medium, and darker pigmentation, re-
spectively (with 
 
111
 
 equivalent to pellet of wtDPPIV in Fig. 4 A and 
 
1111
 
 equivalent to the deeply pigmented pellet observed for melanocytes
in Fig. 4 B).
 
Table II.
 
Range of DPPIV Enzyme Activity
 
dox:
Parental Vector WtDPPIV MutDPPIV
 
21212 1 21
 
Melanoma line
 
pM/min/
 
m
 
g protein
 
 
 
(no. clones tested)
 
MEL-22a 10–30 10–30 10–30 10–30
(6)
20–60 60–310
(7)
20–40 20–60
(3)
SK-MEL-28 10–30 10–30 10–30 10–30
(4)
20–60 240–300
(3)
20–40 20–60
(2)
SK-MEL-29 10–20 10–20 10–20 10–20 20–40 180–220 20–60 20–60
(4) (2) (3)
Parental or transfected melanoma cell lysates were tested for DPPIV activity as described in Materials and Methods. 
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ficult to establish, suggesting that DPPIV expression affected
cell survival or growth. Despite this difficulty, seven different
clones expressing low, medium, and high levels of DPPIV
were selected from MEL-22a transfectants, and two clones
each were isolated for SK-MEL-28 and SK-MEL-29.
DPPIV expression was assessed by three methods: (a) im-
munofluorescence staining, (b) immunoprecipitation from
metabolically labeled cells, and (c) enzymatic activity. Fig. 1
shows DPPIV expression in representative clones of MEL-
22a transfectants, with or without induction by dox. DPPIV
cell surface expression was substantially induced by dox
(Fig. 1 A). Melanoma cells transfected with wtDPPIV and
mutDPPIV expressed the expected 110–120-kD glycopro-
tein, showing that both the wild-type and mutant polypep-
tides were processed and expressed appropriately (Fig. 1 B).
Furthermore, these results showed that mutDPPIV was sta-
ble and expressed at levels comparable to those of wtDPPI.
A weak 110-kD band was detected in parental cells and
cells transfected with empty vector upon long exposure of
autoradiographs (Fig. 1 B), suggesting that melanoma cells
can express very low levels of endogenous DPPIV.
Transfected clones and parental melanoma cells were as-
sessed for DPPIV enzymatic activity (Table II and Fig. 1
C). Parental and vector control–transfected cells expressed
 
#
 
30 pM/min/
 
m
 
g protein of DPPIV activity, which we
believe represents very low endogenous DPPIV activity. In
Figure 1. Expression of DPPIV in transfected melanoma cells. (A) Immunofluorescence microscopy showing expression of DPPIV. MEL-22a cells were
cultured in the presence or absence of dox (2 mg/ml) for 48 h and stained with S27 mAb against DPPIV. Groups include untransfected MEL-22a cells (panel
1) and control vector–transfected cells (panel 2); cells transfected with wtDPPIV and grown in the absence of dox (panel 3) or induced with dox for 48 h
(panel 4); cells transfected with mutDPPIV grown in the absence of dox (panel 5) or induced with dox for 48 h (panel 6). Original magnification 400. (B)
Immunoprecipitation analysis of DPPIV expression in MEL-22a cells transfected with wt- or mutDPPIV. Cells were labeled with [35S]methionine for 18 h,
lysed with 1% NP-40, immunoprecipitated with mAb S27 against DPPIV, analyzed by 9% SDS-PAGE, and visualized by autoradiography. The first and sec-
ond lanes (from left) are untransfected MEL-22a and vector-transfected MEL-22a controls, respectively. The third and fourth lanes are two separate clones of
transfected MEL-22a cells expressing either high (hi) or intermediate (med) levels of wtDPPIV when grown in the presence of dox. The fifth lane is
MEL-22a cells transfected with mutDPPIV grown in the presence of dox. The sixth lane shows wtDPPIVhi-transfected MEL-22a clone grown in the absence
of dox. Arrow, 110–120 kD band of DPPIV. 2, not induced or 1, induced with dox. (C) DPPIV activity in MEL-22a clones transfected with wtDPPIV,
mutDPPIV, or control vector and in cultured normal foreskin melanocytes. Three different clones of MEL-22a cells transfected with wtDPPIV were ana-
lyzed expressing low (wtDPPIVlow), intermediate (wtDPPIVmed), and high (wtDPPIVhi) levels of enzyme activity. Open bars (2dox), enzyme activities in
absence of dox; hatched bars (1dox), enzyme activity after induction with dox. Results shown are mean values 6 1 SD of triplicates. 
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the absence of dox, DPPIV activity in DPPIV-transfected
melanoma cells was 
 
#
 
60 pM/min/
 
m
 
g protein. Peptidase
activity of melanoma cells induced to express high levels of
wtDPPIV in the presence of dox was 220–310 pM/min/
 
m
 
g
protein (Table II and Fig. 1 C). This level was comparable
to that of melanocytes (300–350 pM/min/
 
m
 
g protein; range
from three distinct assays; Fig. 1 C). Despite high expres-
sion of mutDPPIV protein (Fig. 1, A and B), melanoma
cells expressing mutDPPIV exhibited low levels of enzyme
activity even in the presence of dox (
 
#
 
60 pM/min/
 
m
 
g pro-
tein; Table II and Fig. 1 C). Transfected MEL-22a clones
were isolated that expressed high (hi), medium (med), and
low DPPIV activity for more detailed studies to compare
phenotype and level of DPPIV expression (Fig. 1, B and C).
In summary, levels of DPPIV expression were consistent
across the three assays, showing that steady-state level of
protein expression corresponded to wtDPPIV enzymatic
activity. As expected, there was low DPPIV enzyme activity
in cells expressing mutDPPIV. Results of DPPIV activity in
transfected melanoma lines SK-MEL-28 and SK-MEL-29
showed levels similar to those of MEL-22a (Table II). These
results showed that: (a) the maximum level of DPPIV activ-
ity in transfected melanoma cells did not exceed levels ex-
pressed by cultured normal melanocytes (either normalized
to protein concentration or when calculated on a per-cell ba-
sis), (b) dox induced DPPIV expression fivefold or more, and
(c) mutDPPIV expressed minimal or no enzyme activity.
 
Inhibition of Tumorigenicity by Expression of DPPIV.
 
Tu-
morigenicity of melanoma cells expressing wtDPPIV or mut-
DPPIV was compared with that of control melanoma cells.
Nude mice were injected subcutaneously with transfected
and control MEL-22a or SK-MEL-29 melanoma cells (pa-
rental SK-MEL-28 melanoma cells do not form tumors in
immune-compromised mice). Parental and control vector
melanoma cells formed progressive tumors in all mice. Fig. 2,
A and B shows results from two different experiments for
MEL-22a, and Fig. 2 C shows results for SK-MEL-29. Tu-
morigenicity was essentially ablated in MEL-22a cells when
DPPIV was induced to levels expressed by normal melano-
cytes (wtDPPIVhi). Mice showed no progression of tumors
over 100 d (Fig. 2, A and B), although viable tumor cells
remained after 100 d (data not shown). Similar results were
observed with SK-MEL-29 expressing wtDPPIV (Fig. 2 C).
Tumor growth was also reduced in melanoma cells express-
ing medium levels of DPPIV, although not as profoundly as
for high levels of DPPIV (Fig. 2, A and C). Transfected
MEL-22a melanoma cells expressing low levels of DPPIV,
either in the absence of induction of DPPIV (wtDPPIVhi
[
 
2
 
dox], Fig. 2 A) or constitutively (DPPIVlow [
 
1
 
dox], Fig.
2 B), showed slightly reduced tumor growth, perhaps due to
either low levels of DPPIV activity or recruitment of FAP
 
a
 
,
which forms a heterodimer with DPPIV (as discussed below).
Melanoma cells expressing high levels of mutDPPIV formed
tumors at variable rates, with some mice showing inhibi-
tion of tumor growth (note error bars in Fig. 2, A and C
for mutDPPIV). These results were consistent with a require-
ment of DPPIV serine peptidase activity for complete inhibi-
tion of tumorigenicity. However, inconsistent inhibition of
 
tumorigenicity in melanoma cells expressing mutDPPIV sug-
gested that some effects of DPPIV on in vivo tumor growth
were possibly independent of DPPIV serine peptidase activity.
 
Inhibition of Anchorage-independent Growth by Expression of
DPPIV.
 
Another characteristic of malignant cells is anchor-
age-independent growth. Expression of DPPIV led to a
marked decrease in the ability of MEL-22a melanoma cells
to grow in soft agar. DPPIV expression inhibited colony-
forming ability by 
 
z
 
75% in MEL-22a cells, with little inhi-
bition of MEL-22a cells expressing mutDPPIV compared
with parental and vector control cells (Fig. 3). Thus, serine
peptidase activity was required to decrease anchorage-inde-
pendent growth.
 
Phenotypic Changes of Melanoma Cells Expressing DPPIV.
 
Marked morphological changes were observed in melanoma
cells expressing wtDPPIV (Fig. 4 and Table I). Parental
MEL-22a melanoma cells and cells transfected with control
vector or mutDPPIV were a disorganized array of epithe-
lioid, polygonal, and short bipolar spindle-shaped cells and
grew in piled colonies without any apparent organization
(Fig. 4 A). Cells expressing medium or high levels of wt-
DPPIV were consistently long bipolar spindle shaped, with or-
ganized growth behavior and sheet-like appearance, suggesting
organization by cell–cell contact (Fig. 4 A). SK-MEL-28 and
SK-MEL-29 cells also changed morphology from the long
spindle shape of parental-, control vector–, and mutDPPIV-
transfected cells to a more mature polydendritic shape of cells
expressing wtDPPIV (Table I). The polydendritic shape is
characteristic of well-differentiated melanoma cells (17, 18).
We have previously shown that MEL-22a cells have a
block in differentiation associated with a nonpigmented, im-
mature melanocytic phenotype (18). Five MEL-22a clones
expressing medium and high levels of DPPIV were pig-
mented when grown to confluence (Fig. 4 B and Table I).
Three clones expressing mutDPPIV had no pigment. None
of the six clones with control vector nor parental cells were
pigmented (Fig. 4 B and Table I). Differentiation of melano-
cytic cells is characterized not only by appearance of pigmen-
tation but by expression of melanosome membrane glycopro-
teins involved in melanin metabolism. The best characterized
glycoproteins are members of the tyrosinase family, including
tyrosinase and tyrosinase-related proteins (TRP). Expression
of wtDPPIV, but not mutDPPIV, correlated with a markedly
increased expression of human tyrosinase (Fig. 4 C). Expres-
sion of wtDPPIV (but not mutDPPIV) was also associated
with de novo expression of the 
 
brown
 
 locus protein, gp75
 
TRP-1
 
(23), measured by indirect immunofluorescence staining
(data not shown). Expression of gp75
 
TRP-1
 
 and upregulation
of tyrosinase protein occur at a later stage in melanocyte dif-
ferentiation, confirming that the tyrosinase low/gp75
 
TRP-1
 
–
negative MEL-22a had differentiated. Induction of pig-
mentation associated with expression of DPPIV was also
observed in the two other melanoma cell lines, SK-MEL-
28 and -29 (Table I). These observations show that DPPIV
expression is associated with a relief of the block in differ-
entiation of melanoma cells.
 
Growth Characteristics of Melanoma Cells Expressing DPPIV.
 
Expression of DPPIV did not affect growth of MEL-22a 
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Figure 2.
 
cells during the logarithmic growth phase. The doubling time
of cells expressing high wtDPPIV, mutDPPIV, and control
vectors was 36–38 h and was exactly the same as for paren-
tal MEL-22a in culture media containing serum (36 h). How-
ever, melanoma cells expressing medium and high levels of
wtDPPIV had a much longer lag period after plating before
they entered the logarithmic growth phase (4–5 d) com-
pared with parental cells and melanoma cells expressing
mutDPPIV and control vectors (1–2 d). Also, growth of
wtDPPIV cells was inhibited when cells reached a conflu-
ent state, whereas parental melanoma cells and cells ex-
pressing mutDPPIV and control vector continued to grow
and pile up after reaching confluency (Fig. 4 A). Thus, the
total cell number of wtDPPIV cells was decreased by 40%
compared with control melanoma cells or mutDPPIV cells
on days 10–14 after plating. This was due to the delay be- 
317
 
Wesley et al.
 
fore entering logarithmic growth but also perhaps to inhib-
ited growth upon reaching confluency. Thus, wtDPPIV
expression did not affect log growth of MEL-22a cells but
did slow entry into the rapid growth phase and appeared to
induce some level of growth inhibition at cell confluency.
The difficulty in initiating growth might explain in part the
difficulty in establishing transfected clones of melanoma
cells expressing wtDPPIV.
 
Apoptosis and Block of Cell Cycle in Serum-Free Conditions
Induced by DPPIV Expression.
 
Transformed cells are typi-
cally released from dependence on exogenous growth fac-
tors for survival during tumor progression (24). This char-
acteristic applies to melanoma cells, which have been
shown to survive and grow in serum-free culture medium
without addition of exogenous growth factors, whereas
normal melanocytes die over 7–14 d when serum is with-
drawn (25, 26). We had previously shown that loss of
DPPIV expression was associated with acquisition of growth
factor independence during in vitro transformation of me-
lanocytes (14, 13). This observation demonstrated a correla-
tion between DPPIV expression and a requirement for ex-
ogenous growth factors for survival. We investigated this
possible link by growing transfected and parental mela-
noma cells in serum-free conditions.
WtDPPIV, mutDPPIV, and control MEL-22a cells were
serum starved with or without induction of DPPIV by
dox. Parental and vector control cells grew in serum-free
media with only low levels of detectable apoptotic cell
death (z2–3% of cells showed DNA fragmentation by
TUNEL assay over 15 d) (Table III). A minor population
of transfected melanoma cells not induced for wtDPPIV
cells demonstrated cell death in serum-free conditions (21%
of cells at 15 d; (Table III). However, cells induced to ex-
press either wtDPPIV or mutDPPIV with dox showed a
marked, progressive loss of cell viability; the proportion of
apoptotic cells was 15–18% at day 3, 45–53% at day 8, and
62–78% at day 15 (Table III). Similar results were observed
with SK-MEL-29 cells. Only 8% of control vector–trans-
fected cells were apoptotic 8 d after serum withdrawal
compared with 52% of cells expressing wtDPPIV.
The same set of cells was analyzed for cell cycle progres-
sion in serum-free conditions (Fig. 5). wtDPPIVhi expres-
sion induced a cell cycle arrest at the G0/G1 phase, with
62–76% of the cells present in the G0/G1 stage by day 8
compared with only 5–12% of control vector and parental
cells in the G0/G1 (range of percentages from duplicates of
two experiments). Interestingly, cell cycle arrest at the G0/G1
stage was detected in 32% of cells expressing mutDPPIV, in-
termediate between wtDPPIV and melanoma cells not ex-
pressing DPPIV. These results with mutDPPIV suggest ei-
Figure 2. Effects of DPPIV expression on tumorigenicity. (A) Expression
of wtDPPIV was associated with inhibition of tumor growth of melanoma
cells MEL-22a in nude mice. Six different sets of nude mice (BALB/C nu/
nu, n 5 5–6 for each group) were challenged subcutaneously on day 0 with
3 3 106 cells, either parental MEL-22a or transfected with wtDPPIV (with
medium or high levels of expression induced by dox as presented in Fig. 1),
mutDPPIV, or control vector. Cells were induced (1dox) or not induced
(2dox) with dox for 7 d before tumor challenge. Untransfected (MEL-22a)
or vector-transfected cells were used as controls. Tumor diameters were
measured every 2–3 d. Results are presented as mean tumor diameter 6 1
SD. (B) A repeat of the experiment shown in A with 5–6 mice per group
challenged with MEL-22a melanoma cells. The procedure was the same as in
A. (C) Tumorigenicity of SK-MEL-29 melanoma cells, including parental
SK-MEL-29 cells and cells transfected with wtDPPIV, mutDPPIV, or con-
trol vector. 5 3 106 tumor cells were injected subcutaneously on day 0.
Figure 3. Anchorage-independent growth in soft agar. MEL-22a cells
described in Fig. 2 A were cultured in the absence (2) or presence (1) of
dox for 48 h, and 5,000 viable cells were plated in agar in triplicate as de-
scribed in Materials and Methods. Results are mean number of colonies 6 1
SD at 14 d. Results are pooled from two separate experiments.318 A Role for Dipeptidyl Peptidase IV in Malignancy
ther that some other function than serine protease activity
of DPPIV is involved in apoptosis and cell cycle arrest in-
duced by serum withdrawal or that DPPIV interacts with
other molecules that mediate survival and cell cycle effects.
DPPIV Rescues Expression of FAPa. FAPa is a potential
cell surface serine protease that is coexpressed with DPPIV
by melanocytes. Loss of FAPa expression occurs concomi-
tantly with loss of DPPIV expression during in vitro trans-
formation of melanocytes, and expression is also lost in pri-
mary and metastatic melanoma cell lines (14, 15). DPPIV
and FAPa can form heterodimers in addition to homo-
dimers formed by DPPIV (15). Reexpression of either wt-
or mutDPPIV by MEL-22a melanoma cells induced the cell
surface expression of FAPa (Fig. 6). The relative level of
surface expression of FAPa corresponded to the level of
DPPIV expression, irrespective of wild-type or mutant
forms. Thus, DPPIV rescued surface expression of FAPa.
Discussion
Cell surface proteases are generally thought to participate
in malignant transformation and cancer progression by
facilitating invasion and metastasis. Inhibition of surface
proteases can block tumor progression, and aberrant expres-
sion can facilitate tumorigenesis (27). However, cell surface
proteases may also have the opposite effect, suppressing the
malignant phenotype (27). How cell surface proteases play
a role in suppressing the malignant phenotype of human
cancer without interacting with the extracellular matrix is
not well characterized.
Our results show that loss of DPPIV expression is directly
implicated in suppressing the malignant phenotype of mel-
anoma cells. A crucial question arising from these studies is
how a cell surface peptidase might have such pleiotropic ef-
fects on the malignant phenotype of melanoma cells, revers-
Figure 4. Phenotypic changes associated
with DPPIV expression. (A) Morphology of
MEL-22a clones. Untransfected (panel 1)
and control vector–transfected cells (panel 2)
showed short spindle-shaped and polygonal
morphology and grew in unorganized clus-
ters. MutDPPIV-transfected cells (panel 3)
were morphologically similar to control cells.
WtDPPIV-transfected cells (panel 4) showed
long spindle bipolar morphology with more
organized growth and sheet-like appearance.
Original magnification 200. (B) Pigmenta-
tion of MEL-22a clones in cell pellets. Un-
transfected and control vector–transfected
MEL-22a cells were not melanotic (first and
second pellets from left). Minimal pigmenta-
tion was observed in mutDPPIV-transfected
MEL-22a cells (third pellet). Expression of
wtDPPIV led to brown pigmentation (fourth
pellet). Dark brown pigmentation of normal
foreskin melanocytes is shown in the fifth
pellet. (C) Expression of human tyrosinase
detected by Western blot analysis. Lysates
(1% NP-40) of human melanoma cell line
G-MEL or MEL-22a cells, either parental or
transfected with wtDPPIV (med and hi),
mutDPPIV, or control vector were separated
on a 9% SDS-PAGE. After transfer to mem-
brane, tyrosinase was detected as a broad,
z75-kD band using rabbit anti-PEP7H anti-
body against human tyrosinase. Molecular
mass markers are shown, left.319 Wesley et al.
ing tumorigenicity, affecting the differentiation program,
and changing decisions about survival without exogenous
growth factors. DPPIV has several functions, including serine
peptidase activity, binding to extracellular matrix compo-
nents, and complexing adenosine deaminase (3). Thus, each
of these particular functions, presumably handled by differ-
ent domains of the protein, could contribute to suppression
of the malignant phenotype. Serine®alanine mutation did
not suppress tumorigenicity or anchorage-independent
growth, nor did it reverse the block in differentiation, show-
ing that serine peptidase activity is required for these pheno-
typic changes. The different contributions of other domains
and functions of DPPIV and recruitment of FAPa is yet
uncertain. Biochemical and enzymatic studies may give clues
to their potential functions.
Reexpression of DPPIV led to apoptotic cell death upon
serum withdrawal and cell cycle arrest. Unexpectedly, apop-
tosis was also observed in cells expressing mutDPPIV, which
suggests that the rescue of FAPa as a heterodimer with
DPPIV could explain at least part of these proapoptotic ef-
fects. At this point, we have no data to support this notion
other than this correlative observation. However, consis-
tent with this view, a paralogue of FAPa is induced during
tadpole tail resorption, which is essentially a massive pro-
gram of cell death (28), suggesting that a proapoptotic role
of FAPa might be conserved throughout vertebrate evolu-
tion. FAPa contains a potential serine protease site, but the
functions of FAPa protein, including peptidase activity, are
not well characterized. It will be important to determine
whether FAPa has serine protease activity and if this func-
tion might be important for proapoptotic effects induced
by expression of DPPIV. It will also be important to iden-
tify downstream components that are involved in decisions
about melanoma cell survival and how DPPIV and FAPa
participate in these decisions. Pathways for cell survival in
melanocytes are not well understood. However, bcl-2 is
probably a central mediator of resistance to apoptotic death
in melanocytic cells (29, 30), and one speculation is that
DPPIV expression might ultimately intersect with bcl-2.
DPPIV expression may play a crucial role in checking
cell growth of normal melanocytes. This idea is supported
by our observations that loss of DPPIV correlates with
growth factor–independent proliferation of melanoma cells
(13, 14), as well as the experiments described above. One ex-
planation is that DPPIV degrades growth factors required
for survival of melanocytic cells. As our experiments were
performed in strict serum-free conditions, the most likely
Table III. Apoptosis of MEL-22a Human Melanoma Cells 
Expressing DPPIV in Serum-free Conditions
Melanoma line dox
Day
38 1 5
% Apoptosis
MEL-22a parental 2 3.3 2 3.4
Vector 2 2.1 3 2.5
wtDPPIVhi 2 41 8 2 1
wtDPPIVhi 1 17.5 53 78
wtDPPIVmed 1 15 45 62
mutDPPIV 1 17 50 68
Control (parental and vector-transfected) MEL-22a cells or MEL-22a
cells transfected with DPPIV constructs were assessed for apoptosis by
TUNEL assay as described in Materials and Methods. Percent apoptotic
cells was measured by flow cytometry. dox, induction with doxycycline.
Figure 5. Cell cycle analysis of
melanoma cells expressing DPPIV
and FAPa. Expression of both
wt- and mutDPPIV in MEL-22a
cells was associated with changes
in cell cycle. Parental MEL-22a
cells and cells transfected with
control vector, mutDPPIV, and
wtDPPIV were assessed for cell
cycle progression after 8 d of cul-
ture in serum-free media. Num-
ber of cells at each stage of the
cell cycle were measured by flow
cytometry (first peak was G0/G1,
the intervening trough was
S  phase, and the second peak
represented cells in G2/M) and
analyzed by CellFIT and
PC-LYSIS™ software.320 A Role for Dipeptidyl Peptidase IV in Malignancy
source of growth factors is autocrine factors secreted by
melanoma cells. In prostate cancer, autocrine neuropeptides
such as bombesin and endothelin-1 can stimulate the growth
of prostate carcinoma cells, and these growth factors are in-
activated by the cell surface metallopeptidase, neutral endo-
peptidase 24.11 (31). Chemokines are potential substrates
for DPPIV, including RANTES (regulated on activation,
normal T cell expressed and secreted), stromal cell–derived
factors 1a and 1b, IP-10 (IFN-g–inducible protein 10),
monocyte chemotactic proteins 1, -2, and -3, and GCP-2
(granulocyte chemotactic protein 2) (32–36). In addition,
regulatory peptides, including glucagon-like peptide 1 and
2, neuropeptide Y, and peptide YY are DPPIV substrates
(37, 38). It is uncertain whether chemokines or regulatory
peptides could be involved in maintaining the malignant
phenotype of melanoma or whether other substrates of
DPPIV are involved. It will be important to identify sub-
strates of DPPIV that are made as autocrine factors by mel-
anoma cells.
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